BioSpace · May 2025
HepaTx received an NIH/NIDDK Phase I SBIR grant for a proteomic assay to monitor transplanted cells and tissues, supporting its cell-therapy monitoring platform.
Company research
Public company, workplace, funding, and market signals
Overview
HepaTx is a Palo Alto biotech developing off-the-shelf, stem-cell-based regenerative medicine therapies for late-stage liver disease as an alternative to liver transplant. Public databases disagree on funding totals, so the figures below reflect mixed public sources rather than a single source of truth.
Primary product
Hx-001, an off-the-shelf hepatocyte-like cell therapy for late-stage liver disease
Founded
2015
Headquarters
Palo Alto, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Cell therapy / regenerative medicine
Offices
P.O. Box 60850, Palo Alto, CA 94306, United States
Open Positions
0 jobs at Hepatx
No open positions
Check back later for new openings